Teva to acquire world rights (ex Asia)to fasinumab from Regeneron to treat osteoarthritis pain chronic low back pain.
Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced a global agreement to develop and commercialize fasinumab, Regeneron�s investigational NGF antibody in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global commercial value, as well as ongoing research and development costs of approximately $1 billion.
Under a previously announced collaboration agreement with Regeneron, Mitsubishi Tanabe Pharma has exclusive development and commercial rights to fasinumab in Japan, Korea and nine other Asian countries.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins